RELEASE: Metabolon's Metabolomics Platform Cited in Over 3,000 Peer-Reviewed Articles

-The Metabolon metabolomic platform and services are cited in over 3,000 peer-reviewed articles in the life sciences, pharmaceutical/biotechnology, and applied sciences.

RELEASE: Metabolon's Metabolomics Platform Cited in Over 3,000 Peer-Reviewed Articles

-The Metabolon metabolomic platform and services are cited in over 3,000 peer-reviewed articles in the life sciences, pharmaceutical/biotechnology, and applied sciences

Reference metabolomic data accelerates research across multiple disciplines, leading to citation in over 3,000 journals and growing; almost 75 articles published in world-renowned journals in the first two months of 2023 alone

MORRISVILLE, N.C., March 29, 2023 /PRNewswire/ -- Metabolon, Inc., a world leader in providing metabolomics solutions that advance a wide variety of precision medicine, diagnostic, therapeutic development and research applications, has announced today that the results of its metabolomics platform and related services have been cited in more than 3,000 peer-reviewed journals. For more than 20 years, Metabolon has focused on developing and refining its platform to enable the utility of metabolomics in all areas of life science research. Scientific insights backed by Metabolon's high-quality metabolomic results have enabled the company to achieve this historic milestone.

Publications referencing Metabolon, its platform, and its results have appeared in high-impact, world-renowned journals such as Nature, Nature Medicine, Nature Genetics, Cell, Proceedings of the National Academy of Sciences (PNAS), and many others, demonstrates the dramatic increase in awareness and recognition of the importance of metabolomics in research. Metabolon continues to support active collaboration across scientific disciplines, enabling continued growth and adoption among the life sciences and science innovation communities. Metabolon's contribution to scientific studies was cited in its 1,000th peer-reviewed article in 2016 and has been cited in increasing numbers ever since, with nearly 75 cited in January and February 2023 on topics ranging from COVID-19 to inflammation. . As a result, there are now over 3,000 publications citing Metabolon's contributions, and the number continues to grow.

"Metabolon continues to actively engage the scientific communities to highlight the importance of metabolomics in advancing basic science, clinical research and medicine, as well as expanding our understanding of human health and well-being. Metabolomics is unique in providing best link to functional and phenotypic attributes, which help translate biology from discovery to clinical development and is complementary to gene-based applications in the pharmaceutical industry," said Rohan (Ro) Hastie, CEO of Metabolon. "We are dedicated to providing this important building block to advance research across disease states and ultimately revolutionize drug development."

"Citations for Metabolon's metabolomics platform products and services across this breadth of scientific disciplines underscore the impact of metabolomics in these fields of study," said Ranga Sarangarajan, Metabolon's Chief Scientific Officer. "This milestone shows how we are transforming the way scientists approach incorporating metabolomics into all applicable areas of science, including life sciences, health, and wellness research. Metabolon is dedicated to providing metabolomic results of high quality to various disciplines, as well as the development of tools and capabilities for advanced statistical analysis, the integration of multi-omics data and the use of machine learning and artificial intelligence analysis".

With over 20 years of experience, over 45 PhDs on staff and over 5,400 metabolites in its reference library, Metabolon has completed over 10,000 projects on behalf of clients and partners in the biopharmaceutical, population health , consumer products, agriculture, wellness, and academic and government research. For more information, visit

About Metabolon

Metabolon, Inc. is the world leader in metabolomics, with a mission to provide biochemical data and insights that amplify and accelerate the impact of life science research. Through 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. The Metabolon Global Discovery Panel is powered by the world's largest proprietary metabolomic reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and improving development success. The company offers scalable and customizable lipidomics and metabolomics solutions that meet customer needs from discovery to clinical trials to product lifecycle management. For more information, visit and follow us on LinkedIn and Twitter.

About Metabolomics

Metabolomics, the large-scale study of all the small molecules in a biological system, is the only omics technology that provides a complete functional readout of the current state of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biologic pathways in the body, metabolomics can reveal important biomarkers that can better understand a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to treatment.

Logo -

View original content: